Gujarat Themis Biosyn Ltd vs Morepen Laboratories Ltd Stock Comparison

Home

Insights

Stock Comparison

Last Updated on: Jun 14, 2026

Key Highlights

The Latest Trading Price of Gujarat Themis Biosyn Ltd is ₹ 387.65 as of 12 Jun 15:30 . The P/E Ratio of Gujarat Themis Biosyn Ltd changed from 0 on March 2021 to 0 on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe P/E Ratio of Morepen Laboratories Ltd changed from 14.9 on March 2021 to 22.3 on March 2025 . This represents a CAGR of 8.40% over 5 years The Market Cap of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore on March 2021 to ₹ 0 crore on March 2025 . This represents a CAGR of 0.0% over 5 yearsThe Market Cap of Morepen Laboratories Ltd changed from ₹ 1446 crore on March 2021 to ₹ 2621 crore on March 2025 . This represents a CAGR of 12.64% over 5 years The revenue of Gujarat Themis Biosyn Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 revenue of ₹ 0 crore. This represent the decline of 0% The revenue of Morepen Laboratories Ltd for the Mar '26 is ₹ 493.18 crore as compare to the Dec '25 revenue of ₹ 487.97 crore. This represent the growth of 1.07% The ebitda of Gujarat Themis Biosyn Ltd for the Mar '26 is ₹ 0 crore as compare to the Dec '25 ebitda of ₹ 0 crore. This represent the decline of 0% The ebitda of Morepen Laboratories Ltd for the Mar '26 is ₹ 32.91 crore as compare to the Dec '25 ebitda of ₹ 50.12 crore. This represent the decline of -34.34% The net profit of Gujarat Themis Biosyn Ltd changed from ₹ 0 crore to ₹ 0 crore over 8 quarters. This represents a CAGR of 0.0% The net profit of Morepen Laboratories Ltd changed from ₹ 36.17 crore to ₹ 15.7 crore over 8 quarters. This represents a CAGR of -34.12% The Dividend Payout of Gujarat Themis Biosyn Ltd changed from 36.62 % on March 2022 to 14.97 % on March 2025 . This represents a CAGR of -20.04% over 4 yearsThe Dividend Payout of Morepen Laboratories Ltd changed from 10.79 % on March 2025 to 10.79 % on March 2025 . This represents a CAGR of 0.00% over 1 years .

About Gujarat Themis Biosyn Ltd

Promoted byJayshree D Patel, Gujarat Themis Biosyn Limited (GTBL) was incorporated in 1981 as a joint sector company with Gujarat Industrial Investment Corporation Ltd (GIIC) and Chemosyn (P) Ltd. The Company commenced production in August 1985.
It was subsequently taken over in June 1991 by Yuhan Group, South Korea and Pharmaceutical Business Group (India) Ltd. (PBG); a unique consortium of five competing drug companies - Themis Medicare Ltd., Kopran Ltd., Anant & Co., Cadila Health Care Ltd. (Zydus) and Lyka Labs Ltd. It is actively managed by Themis Medicare Ltd. (JV company of Gedeon Richter Ltd, Hungary) since 2007. Initially manufacturing the antibiotic, erythromycin, GTBL obtained licences to manufacture bulk drugs like rifampicin, cephalexin, griseofulvin and their formulations in 1990.

About Morepen Laboratories Ltd

Morepen Laboratories Limited is an India-based pharmaceutical company.
Its products include Loratadine, Montelukast Sodium, Atorvastatin Calcium and Sultamicillin.
The company markets formulation products in various therapeutic categories, such as antibiotics, gastrointestinal, respiratory, analgesic, antiallergic and neuropsychiatry with brands, such as Saltum, Saltumax, Cefpopen, Cefpen-S, Dom-DT, Acifix, Rabipen- DSR and Montelast.
It has new products added to the therapeutic categories, including Kilbac, Ducal D, Aclomore and Montelast-L. The company has three state-of-the-art manufacturing plants in the northern state of Himachal Pradesh (HP) in India.
The main plant at Parwanoo is inspected and approved by United States Food and Drug Administration (USFDA) for production of Loratadine, which is the best selling anti-allergy drug globally.

FAQs for the comparison of Gujarat Themis Biosyn Ltd and Morepen Laboratories Ltd

Which company has a larger market capitalization, Gujarat Themis Biosyn Ltd or Morepen Laboratories Ltd?

Market cap of Gujarat Themis Biosyn Ltd is 4,224 Cr while Market cap of Morepen Laboratories Ltd is 2,748 Cr

What are the key factors driving the stock performance of Gujarat Themis Biosyn Ltd and Morepen Laboratories Ltd?

The stock performance of Gujarat Themis Biosyn Ltd and Morepen Laboratories Ltd is primarily driven by its robust global client base, consistent revenue growth, strong operational efficiency, strategic investments in digital transformation, client acquisition, and the overall health of the industry. Both companies' performances are also influenced by macroeconomic conditions, currency fluctuations, and industry-specific trends.

What are the recent stock price for Gujarat Themis Biosyn Ltd and Morepen Laboratories Ltd?

As of June 14, 2026, the Gujarat Themis Biosyn Ltd stock price is INR ₹387.65. On the other hand, Morepen Laboratories Ltd stock price is INR ₹50.16.

How do dividend payouts of Gujarat Themis Biosyn Ltd and Morepen Laboratories Ltd compare?

To compare the dividend payouts of Gujarat Themis Biosyn Ltd and Morepen Laboratories Ltd, examine their dividend payout ratio, which indicates how much the companies pay out relative to their share price and earnings. Moreover, consider the consistency and growth of their dividends to gauge their commitment towards returning value to the respective shareholders.

Disclaimer: This information provided above is for informational purposes only and does not constitute investment advice. We use third-party data and recommend conducting thorough research and consulting a certified financial advisor before making investment decisions. We do not endorse specific stocks. Make decisions based on your own research and professional guidance.